A phase I open label multicentre trial of figitumumab, an insulin-like growth factor 1 receptor (IGFR-1R) antibody, in children aged 1 - 12 years old with relapsed/refractory solid tumour.

Trial Profile

A phase I open label multicentre trial of figitumumab, an insulin-like growth factor 1 receptor (IGFR-1R) antibody, in children aged 1 - 12 years old with relapsed/refractory solid tumour.

Completed
Phase of Trial: Phase I

Latest Information Update: 09 Oct 2017

At a glance

  • Drugs Figitumumab (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Acronyms FOREST
  • Most Recent Events

    • 01 Aug 2012 Status changed from recruiting to completed as reported by ISRCTN: Current Controlled Trials.
    • 21 Jun 2010 New trial record
    • 15 Jun 2010 Actual end date (1 Aug 2012) added as reported by ISRCTN: Current Controlled Trials.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top